{"id":17917,"date":"2024-02-07T12:46:34","date_gmt":"2024-02-07T11:46:34","guid":{"rendered":"https:\/\/www.hematostat.net\/?p=17917"},"modified":"2024-02-07T12:50:25","modified_gmt":"2024-02-07T11:50:25","slug":"dreamm-7-etude-de-phase-3-qui-montre-avec-blenrep-en-combinaison-un-quasi-triplement-de-la-survie-sans-progression-par-rapport-a-une-combinaison-standard","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/dreamm-7-etude-de-phase-3-qui-montre-avec-blenrep-en-combinaison-un-quasi-triplement-de-la-survie-sans-progression-par-rapport-a-une-combinaison-standard\/","title":{"rendered":"DreaMM 7, \u00e9tude de phase 3 qui montre avec Blenrep en combinaison un quasi triplement de la survie sans progression par rapport \u00e0 une combinaison standard"},"content":{"rendered":"<p>Les r\u00e9sultats d\u2019une \u00e9tude de sup\u00e9riorit\u00e9 de phase 3 d\u2019enregistrement de Blenrep\u00a0en combinaison (DreaMM 7), montrent un quasi triplement de la survie sans progression\u00a0par rapport \u00e0 une combinaison standard : soit 36,6 mois pour la combinaison Blenrep <em>vs<\/em> 13,4 mois pour le traitement standard\u00a0et une r\u00e9duction du risque de progression\u00a0ou de d\u00e9c\u00e8s de 59%.<\/p>\n<p>Ces r\u00e9sultats ont notamment \u00e9t\u00e9 partag\u00e9s hier, lors d\u2019une session virtuelle de l\u2019ASCO.<\/p>\n<p>Cette analyse interm\u00e9diaire montre \u00e9galement une tendance forte et cliniquement significative sur l\u2019am\u00e9lioration de la survie globale, avec une r\u00e9duction du risque de d\u00e9c\u00e8s de 43%. Les donn\u00e9es matures sont tr\u00e8s attendues au regard de ces r\u00e9sultats pr\u00e9liminaires. Cette combinaison de Blenrep va apporter une nouvelle option tr\u00e8s importante\u00a0pour les patients atteints de my\u00e9lome multiple en rechute pr\u00e9coce.<\/p>\n<p>Les r\u00e9sultats de DreaMM 8, autre combinaison de Blenrep en rechute pr\u00e9coce, sont \u00e9galement attendus prochainement.<\/p>\n<p style=\"text-align: right;\"><em>D&#8217;apr\u00e8s un communiqu\u00e9 de presse de GSK le 7 f\u00e9vrier 2024.<\/em><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Les r\u00e9sultats d\u2019une \u00e9tude de sup\u00e9riorit\u00e9 de phase 3 d\u2019enregistrement de Blenrep\u00a0en combinaison (DreaMM 7), montrent un quasi triplement de la survie sans progression\u00a0par rapport \u00e0 une combinaison standard : [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[441],"class_list":["post-17917","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-admin6779"],"aioseo_notices":[],"authors":[{"term_id":441,"user_id":1,"is_guest":0,"slug":"admin6779","display_name":"HematoStat.net","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/4f64711e55fa3c9401676697c4783cec15305a6f940a0f120048b6141a611347?s=96&d=mm&r=g","first_name":"HematoStat.net","last_name":"","user_url":"http:\/\/www.hematostat.net","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=17917"}],"version-history":[{"count":2,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17917\/revisions"}],"predecessor-version":[{"id":17919,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17917\/revisions\/17919"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=17917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=17917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=17917"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=17917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}